Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
25 and 50 mg diclofenac K film coated immediate release tablets More
The First Line of Therapy in Severe Migraine Attacks More
Novel Dual Chamber Dispenser with polycarbonate and stainless steel components for accurate Rx dosing. More
Locally applied and locally acting NSAID Matrix Patch containing 140 mg Diclofenac Sodium More
FMC Pharma is devoted to the treatment of osteoarthritis through the development of products, marketing methodologies and out-licensing opportunities. More
BIS010 is a semi-synthetic plant origin polysaccharide demonstrating a potential modifying effect of the biologic activity of the joints. More
NSAI, antioxidant, 5-LO inhibitor, and polyethoxylated castor oil compositions available for license. More
New pyridinic sulfonamide derivatives for the treatment and/or prevention of diseases such as inflammation, arthrosis, cancer and angiogenesis and for other pathologies in which they can play a role as COX-2 selective inhibitors. More
L-histidine is being developed as a prescription drug and as a dietary supplement for 1) chronic inflammatory gastrointestinal diseases; 2) conjunctivitis and seasonal allergic rhinitis; 3) infectious and non-infectious diarrheas; and 4) as an antioxidant More
The University of Edinburgh has identified a hitherto unrecognised potential of IKr-specific Class III anti-arrhythmics for the treatment of inflammatory disorders in a number of disease states/models. More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Therapeutic target
- Cachexia
- Cervical dystonia
- Inflammation
- Muscular dystrophy
- Myasthenia gravis
- Spasticity
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us